Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo U.S. CEO Joe Pieroni: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

This article was originally published in The Pink Sheet Daily

Executive Summary

Exec discusses the anti-platelet drug prasugrel that Daiichi is developing with Lilly, Daiichi’s planned sales force expansion, and his views on partnering in the U.S. and Asia.

You may also be interested in...



Astellas, Daiichi Move Ahead With Factor Xa Programs

Astellas and Daiichi Sankyo both are on track to proceed to Phase III for their respective oral Factor Xa inhibitors, the companies indicated in second quarter earnings presentations on Nov. 7

Astellas, Daiichi Move Ahead With Factor Xa Programs

Japanese pharmas, each in Phase IIb with their oral Factor Xa inhibitors, are behind J&J/Bayer and Bristol/Pfizer, which have Phase III candidates.

Astellas, Daiichi Move Ahead With Factor Xa Programs

Japanese pharmas, each in Phase IIb with their oral Factor Xa inhibitors, are behind J&J/Bayer and Bristol/Pfizer, which have Phase III candidates.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel